Clinical Trial Update: Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 neoadjuvant trial evaluating durvalumab with tremelimumab, with and without chemotherapy, for malignant mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Mesothelioma | Phase 1, Phase 2 | Status: RECRUITING